Innovations in Surgical Cameras and Their Impact on Healthcare

Food Allergy Market - Emerging Therapies, And Understanding the Market Barriers and Future Scope

Food Allergy is an Immune System reaction which usually occurs on eating any specific food. The reaction to Food Allergy can be mild, but for some people, it can become deadly, and the Food Allergy Symptoms vary from person to person. Food Allergy market insights provides a more in-depth details about the Food Allergy market and all the ongoing developments and will evaluate the Upcoming drugs in the Pipeline for Food Allergy Treatment. There are many common Food Allergies which can be seen among people, but Food Allergy Clinical Trials are way ahead to be launched on a functional way still, there is no promised diagnosis for Food Allergy Testing.

PALFORZIA, is the only marketed and the first FDA-approved food allergy treatment, which was developed by Aimmune and bought up by Nestle in October 2020, and was approved as Oral Immunotherapy (OIT) on January 31, 2020. FDA approved it as a mitigation for allergic reactions, including anaphylaxis, that occurs due to the accidental peanut exposure for patients aged 4 to 17 years, with a confirmed diagnosis of peanut allergy. 

Emerging Therapies for the Food Allergy Treatment-

There are many companies working on the development of Food Allergy Therapies and many emerging Food Allergy Pipeline drugs are in various clinical phases like- Aimmune Therapeutics, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Regeneron Pharmaceuticals, Genentech, Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics,Inc., Camallergy, and others are currently involved in the development of various food allergy drugs. 

Many companies are still developing therapies for the Food Allergy treatment and are in different phases of the clinical trails, such as-

Drug	Company	Phase	MoA
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT	NIAID)/Genentech	Inc./Novartis Pharmaceuticals	Phase III
Ligelizumab	Novartis	Phase III	Immunoglobulin E inhibitors
CA002	Camallergy	Phase II	Immunomodulators
VE416	Vedanta Biosciences	Phase I/II	Immunomodulators; Microbiome modulators; Regulatory T-lymphocyte stimulants
ADP101	Alladapt Immunotherapeutics	Phase I/II	Immunomodulators
INP20	InnoUp Pharma	Phase I/II	Immunostimulants
CNP-201	COUR Pharmaceuticals	Phase I/II	Immunomodulators

Expected Roadblocks for the Food Allergy Treatment-

From the past decades, diagnostic research and development have led to a better understanding of the Food Allergy conditions. However, there are still many factors which are affecting the growth of the Food Allergy treatment market. Due to the lack of understanding of the mechanism of the Food Allergy, it is often diagnosed by relating it to other Food Allergies or diseases. And the prevalence of food allergies is further underestimated due to different symptoms observed in the different people for the same food allergy, and the unwillingness of people to disclose the symptoms they feel over any certain food allergy makes the diagnosis of the food allergy more complicated.

Way ahead to a better Food Allergy Treatment-

Due to many barriers in between, researchers are continuously trying to find a proper treatment for the Common Food Allergies. Food Allergy testing has still to pass many underlying barriers from the society, where people are seeking for a preventive rather than a curative therapy treatment. Increasing patient awareness about the Food Allergies, continuous development in the Food Allergy Pipeline and more improved diagnostics will drive the Food Allergy Treatment market in the future ahead.